Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 507 entries
Sorted by: Best Match Show Resources per page
Combination Therapy for Gliomas Using Temozolomide and Interferon-Beta Secreting Human Bone Marrow Derived Mesenchymal Stem Cells.

Journal of Korean Neurosurgical Society

Park JH, Ryu CH, Kim MJ, Jeun SS.
PMID: 26113958
J Korean Neurosurg Soc. 2015 May;57(5):323-8. doi: 10.3340/jkns.2015.57.5.323. Epub 2015 May 31.

OBJECTIVE: Malignant gliomas are the most common primary tumors of the central nervous system and the prognosis of patients with gliomas is poor. The combination of interferon-bata (IFN-β) and temozolomide (TMZ) has shown significant additive antitumor effects in human...

Cite
Park JH, Ryu CH, Kim MJ, et al. Combination Therapy for Gliomas Using Temozolomide and Interferon-Beta Secreting Human Bone Marrow Derived Mesenchymal Stem Cells. J Korean Neurosurg Soc. 2015;57(5):323-8doi: 10.3340/jkns.2015.57.5.323.
Park, J. H., Ryu, C. H., Kim, M. J., & Jeun, S. S. (2015). Combination Therapy for Gliomas Using Temozolomide and Interferon-Beta Secreting Human Bone Marrow Derived Mesenchymal Stem Cells. Journal of Korean Neurosurgical Society, 57(5), 323-8. https://doi.org/10.3340/jkns.2015.57.5.323
Park, Jae-Hyun, et al. "Combination Therapy for Gliomas Using Temozolomide and Interferon-Beta Secreting Human Bone Marrow Derived Mesenchymal Stem Cells." Journal of Korean Neurosurgical Society vol. 57,5 (2015): 323-8. doi: https://doi.org/10.3340/jkns.2015.57.5.323
Park JH, Ryu CH, Kim MJ, Jeun SS. Combination Therapy for Gliomas Using Temozolomide and Interferon-Beta Secreting Human Bone Marrow Derived Mesenchymal Stem Cells. J Korean Neurosurg Soc. 2015 May;57(5):323-8. doi: 10.3340/jkns.2015.57.5.323. Epub 2015 May 31. PMID: 26113958; PMCID: PMC4479712.
Copy Download .nbib Format: NLM
Optimization of Fermentation Conditions for Recombinant Human Interferon Beta Production by Escherichia coli Using the Response Surface Methodology.

Jundishapur journal of microbiology

Morowvat MH, Babaeipour V, Rajabi Memari H, Vahidi H.
PMID: 26034535
Jundishapur J Microbiol. 2015 Apr 18;8(4):e16236. doi: 10.5812/jjm.8(4)2015.16236. eCollection 2015 Apr.

BACKGROUND: The periplasmic overexpression of recombinant human interferon beta (rhIFN-β)-1b using a synthetic gene in Escherichia coli BL21 (DE3) was optimized in shake flasks using Response Surface Methodology (RSM) based on the Box-Behnken Design (BBD).OBJECTIVES: This study aimed to...

Cite
Morowvat MH, Babaeipour V, Rajabi Memari H, et al. Optimization of Fermentation Conditions for Recombinant Human Interferon Beta Production by Escherichia coli Using the Response Surface Methodology. Jundishapur J Microbiol. 2015;8(4):e16236doi: 10.5812/jjm.8(4)2015.16236.
Morowvat, M. H., Babaeipour, V., Rajabi Memari, H., & Vahidi, H. (2015). Optimization of Fermentation Conditions for Recombinant Human Interferon Beta Production by Escherichia coli Using the Response Surface Methodology. Jundishapur journal of microbiology, 8(4), e16236. https://doi.org/10.5812/jjm.8(4)2015.16236
Morowvat, Mohammad Hossein, et al. "Optimization of Fermentation Conditions for Recombinant Human Interferon Beta Production by Escherichia coli Using the Response Surface Methodology." Jundishapur journal of microbiology vol. 8,4 (2015): e16236. doi: https://doi.org/10.5812/jjm.8(4)2015.16236
Morowvat MH, Babaeipour V, Rajabi Memari H, Vahidi H. Optimization of Fermentation Conditions for Recombinant Human Interferon Beta Production by Escherichia coli Using the Response Surface Methodology. Jundishapur J Microbiol. 2015 Apr 18;8(4):e16236. doi: 10.5812/jjm.8(4)2015.16236. eCollection 2015 Apr. PMID: 26034535; PMCID: PMC4449858.
Copy Download .nbib Format: NLM
Multiple sclerosis therapy and Epstein-Barr virus antibody titres.

Multiple sclerosis and related disorders

Raffel J, Dobson R, Gafson A, Mattoscio M, Muraro P, Giovannoni G.
PMID: 25876475
Mult Scler Relat Disord. 2014 May;3(3):372-4. doi: 10.1016/j.msard.2013.12.004. Epub 2013 Dec 31.

BACKGROUND: Anti-Epstein-Barr virus (EBV) nuclear antigen-1 (anti-EBNA-1) IgG antibody titres have been found to correlate with MRI and clinical measures of disease activity in MS. Despite being a putative biomarker of disease activity, the effect of disease modifying drugs...

Cite
Raffel J, Dobson R, Gafson A, et al. Multiple sclerosis therapy and Epstein-Barr virus antibody titres. Mult Scler Relat Disord. 2013;3(3):372-4doi: 10.1016/j.msard.2013.12.004.
Raffel, J., Dobson, R., Gafson, A., Mattoscio, M., Muraro, P., & Giovannoni, G. (2014). Multiple sclerosis therapy and Epstein-Barr virus antibody titres. Multiple sclerosis and related disorders, 3(3), 372-4. https://doi.org/10.1016/j.msard.2013.12.004
Raffel, Joel, et al. "Multiple sclerosis therapy and Epstein-Barr virus antibody titres." Multiple sclerosis and related disorders vol. 3,3 (2014): 372-4. doi: https://doi.org/10.1016/j.msard.2013.12.004
Raffel J, Dobson R, Gafson A, Mattoscio M, Muraro P, Giovannoni G. Multiple sclerosis therapy and Epstein-Barr virus antibody titres. Mult Scler Relat Disord. 2014 May;3(3):372-4. doi: 10.1016/j.msard.2013.12.004. Epub 2013 Dec 31. PMID: 25876475.
Copy Download .nbib Format: NLM
Natural interferon-beta plus ribavirin therapy led to sustained virological response after seven unsuccessful courses of anti-viral treatment in a chronic hepatitis C patient.

Clinical journal of gastroenterology

Kanda T, Nakamoto S, Arai M, Miyamura T, Wu S, Fujiwara K, Yokosuka O.
PMID: 26181455
Clin J Gastroenterol. 2013 Apr;6(2):160-3. doi: 10.1007/s12328-013-0366-1. Epub 2013 Feb 17.

We describe a patient infected with hepatitis C virus (HCV) genotype 1 who failed to respond to interferon with or without ribavirin seven times but who then achieved sustained virological response by the combination of interferon-beta plus ribavirin treatment...

Cite
Kanda T, Nakamoto S, Arai M, et al. Natural interferon-beta plus ribavirin therapy led to sustained virological response after seven unsuccessful courses of anti-viral treatment in a chronic hepatitis C patient. Clin J Gastroenterol. 2013;6(2):160-3doi: 10.1007/s12328-013-0366-1.
Kanda, T., Nakamoto, S., Arai, M., Miyamura, T., Wu, S., Fujiwara, K., & Yokosuka, O. (2013). Natural interferon-beta plus ribavirin therapy led to sustained virological response after seven unsuccessful courses of anti-viral treatment in a chronic hepatitis C patient. Clinical journal of gastroenterology, 6(2), 160-3. https://doi.org/10.1007/s12328-013-0366-1
Kanda, Tatsuo, et al. "Natural interferon-beta plus ribavirin therapy led to sustained virological response after seven unsuccessful courses of anti-viral treatment in a chronic hepatitis C patient." Clinical journal of gastroenterology vol. 6,2 (2013): 160-3. doi: https://doi.org/10.1007/s12328-013-0366-1
Kanda T, Nakamoto S, Arai M, Miyamura T, Wu S, Fujiwara K, Yokosuka O. Natural interferon-beta plus ribavirin therapy led to sustained virological response after seven unsuccessful courses of anti-viral treatment in a chronic hepatitis C patient. Clin J Gastroenterol. 2013 Apr;6(2):160-3. doi: 10.1007/s12328-013-0366-1. Epub 2013 Feb 17. PMID: 26181455.
Copy Download .nbib Format: NLM
Proteomic profiling change during the early development of silicosis disease.

Journal of thoracic disease

Miao R, Ding B, Zhang Y, Xia Q, Li Y, Zhu B.
PMID: 27076927
J Thorac Dis. 2016 Mar;8(3):329-41. doi: 10.21037/jtd.2016.02.46.

BACKGROUND: Silicosis is one of several severe occupational diseases for which effective diagnostic tools during early development are currently unavailable. In this study we focused on proteomic profiling during the early stages of silicosis to investigate the pathophysiology and...

Cite
Miao R, Ding B, Zhang Y, et al. Proteomic profiling change during the early development of silicosis disease. J Thorac Dis. 2016;8(3):329-41doi: 10.21037/jtd.2016.02.46.
Miao, R., Ding, B., Zhang, Y., Xia, Q., Li, Y., & Zhu, B. (2016). Proteomic profiling change during the early development of silicosis disease. Journal of thoracic disease, 8(3), 329-41. https://doi.org/10.21037/jtd.2016.02.46
Miao, Rongming, et al. "Proteomic profiling change during the early development of silicosis disease." Journal of thoracic disease vol. 8,3 (2016): 329-41. doi: https://doi.org/10.21037/jtd.2016.02.46
Miao R, Ding B, Zhang Y, Xia Q, Li Y, Zhu B. Proteomic profiling change during the early development of silicosis disease. J Thorac Dis. 2016 Mar;8(3):329-41. doi: 10.21037/jtd.2016.02.46. PMID: 27076927; PMCID: PMC4805820.
Copy Download .nbib Format: NLM
Interferon beta-1a-induced morphea.

JAAD case reports

Bezalel SA, Strober BE, Ferenczi K.
PMID: 27075128
JAAD Case Rep. 2014 Oct 05;1(1):15-7. doi: 10.1016/j.jdcr.2014.10.002. eCollection 2015 Jan.

No abstract available.

Cite
Bezalel SA, Strober BE, Ferenczi K. Interferon beta-1a-induced morphea. JAAD Case Rep. 2014;1(1):15-7doi: 10.1016/j.jdcr.2014.10.002.
Bezalel, S. A., Strober, B. E., & Ferenczi, K. (2015). Interferon beta-1a-induced morphea. JAAD case reports, 1(1), 15-7. https://doi.org/10.1016/j.jdcr.2014.10.002
Bezalel, Spencer A, et al. "Interferon beta-1a-induced morphea." JAAD case reports vol. 1,1 (2015): 15-7. doi: https://doi.org/10.1016/j.jdcr.2014.10.002
Bezalel SA, Strober BE, Ferenczi K. Interferon beta-1a-induced morphea. JAAD Case Rep. 2014 Oct 05;1(1):15-7. doi: 10.1016/j.jdcr.2014.10.002. eCollection 2015 Jan. PMID: 27075128; PMCID: PMC4802549.
Copy Download .nbib Format: NLM
Natural interferon-beta in chronic progressive multiple sclerosis: results after 2 years of treatment and 2 years of follow up.

European journal of neurology

Ghezzi A, Zaffaroni M, Filippi M, Reganati P, Zibetti A.
PMID: 24283615
Eur J Neurol. 1995 Apr;2(2):139-41. doi: 10.1111/j.1468-1331.1995.tb00107.x.

Seventeen chronic progressive multiple sclerosis patients were treated with natural interferon-beta (IFN-β) for 2 years, thereafter they were followed up for 2 years. IFN-β was given 1 million IU/day i.m. for 1 week, then 3 million IU daily for...

Cite
Ghezzi A, Zaffaroni M, Filippi M, et al. Natural interferon-beta in chronic progressive multiple sclerosis: results after 2 years of treatment and 2 years of follow up. Eur J Neurol. 1995;2(2):139-41doi: 10.1111/j.1468-1331.1995.tb00107.x.
Ghezzi, A., Zaffaroni, M., Filippi, M., Reganati, P., & Zibetti, A. (1995). Natural interferon-beta in chronic progressive multiple sclerosis: results after 2 years of treatment and 2 years of follow up. European journal of neurology, 2(2), 139-41. https://doi.org/10.1111/j.1468-1331.1995.tb00107.x
Ghezzi, A, et al. "Natural interferon-beta in chronic progressive multiple sclerosis: results after 2 years of treatment and 2 years of follow up." European journal of neurology vol. 2,2 (1995): 139-41. doi: https://doi.org/10.1111/j.1468-1331.1995.tb00107.x
Ghezzi A, Zaffaroni M, Filippi M, Reganati P, Zibetti A. Natural interferon-beta in chronic progressive multiple sclerosis: results after 2 years of treatment and 2 years of follow up. Eur J Neurol. 1995 Apr;2(2):139-41. doi: 10.1111/j.1468-1331.1995.tb00107.x. PMID: 24283615.
Copy Download .nbib Format: NLM
Financial and Clinical Implications of Intramuscular Versus Subcutaneous Interferon Beta-1a in Portugal, Based on the Findings from the Cochrane Collaboration Review of First-Line Treatments for Relapsing-Remitting Multiple Sclerosis.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Silverio N, Sequeira L, Meletiche D.
PMID: 27200931
Value Health. 2014 Nov;17(7):A396. doi: 10.1016/j.jval.2014.08.887. Epub 2014 Oct 26.

No abstract available.

Cite
Silverio N, Sequeira L, Meletiche D. Financial and Clinical Implications of Intramuscular Versus Subcutaneous Interferon Beta-1a in Portugal, Based on the Findings from the Cochrane Collaboration Review of First-Line Treatments for Relapsing-Remitting Multiple Sclerosis. Value Health. 2014;17(7):A396doi: 10.1016/j.jval.2014.08.887.
Silverio, N., Sequeira, L., & Meletiche, D. (2014). Financial and Clinical Implications of Intramuscular Versus Subcutaneous Interferon Beta-1a in Portugal, Based on the Findings from the Cochrane Collaboration Review of First-Line Treatments for Relapsing-Remitting Multiple Sclerosis. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A396. https://doi.org/10.1016/j.jval.2014.08.887
Silverio, N, et al. "Financial and Clinical Implications of Intramuscular Versus Subcutaneous Interferon Beta-1a in Portugal, Based on the Findings from the Cochrane Collaboration Review of First-Line Treatments for Relapsing-Remitting Multiple Sclerosis." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A396. doi: https://doi.org/10.1016/j.jval.2014.08.887
Silverio N, Sequeira L, Meletiche D. Financial and Clinical Implications of Intramuscular Versus Subcutaneous Interferon Beta-1a in Portugal, Based on the Findings from the Cochrane Collaboration Review of First-Line Treatments for Relapsing-Remitting Multiple Sclerosis. Value Health. 2014 Nov;17(7):A396. doi: 10.1016/j.jval.2014.08.887. Epub 2014 Oct 26. PMID: 27200931.
Copy Download .nbib Format: NLM
Natural interferon-beta treatment for patients with chronic hepatitis C in Japan.

World journal of hepatology

Sasaki R, Kanda T, Nakamoto S, Haga Y, Nakamura M, Yasui S, Jiang X, Wu S, Arai M, Yokosuka O.
PMID: 26052401
World J Hepatol. 2015 May 18;7(8):1125-32. doi: 10.4254/wjh.v7.i8.1125.

Chronic hepatitis C virus (HCV) infection can cause liver cirrhosis and hepatocellular carcinoma (HCC). Several studies have demonstrated that the eradication of HCV reduces the occurrence of HCC. In Japan, as many people live to an advanced age, HCV-infected...

Cite
Sasaki R, Kanda T, Nakamoto S, et al. Natural interferon-beta treatment for patients with chronic hepatitis C in Japan. World J Hepatol. 2015;7(8):1125-32doi: 10.4254/wjh.v7.i8.1125.
Sasaki, R., Kanda, T., Nakamoto, S., Haga, Y., Nakamura, M., Yasui, S., Jiang, X., Wu, S., Arai, M., & Yokosuka, O. (2015). Natural interferon-beta treatment for patients with chronic hepatitis C in Japan. World journal of hepatology, 7(8), 1125-32. https://doi.org/10.4254/wjh.v7.i8.1125
Sasaki, Reina, et al. "Natural interferon-beta treatment for patients with chronic hepatitis C in Japan." World journal of hepatology vol. 7,8 (2015): 1125-32. doi: https://doi.org/10.4254/wjh.v7.i8.1125
Sasaki R, Kanda T, Nakamoto S, Haga Y, Nakamura M, Yasui S, Jiang X, Wu S, Arai M, Yokosuka O. Natural interferon-beta treatment for patients with chronic hepatitis C in Japan. World J Hepatol. 2015 May 18;7(8):1125-32. doi: 10.4254/wjh.v7.i8.1125. PMID: 26052401; PMCID: PMC4450189.
Copy Download .nbib Format: NLM
Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis.

Therapeutics and clinical risk management

Cocco E, Marrosu MG.
PMID: 26056458
Ther Clin Risk Manag. 2015 May 08;11:759-66. doi: 10.2147/TCRM.S69123. eCollection 2015.

Several treatments are currently available for relapsing-remitting multiple sclerosis. Among them, interferon (IFN) beta remains a valid treatment approach because of its good benefit/risk profile. Due to the need for frequent administration (weekly, at a minimum), the use of...

Cite
Cocco E, Marrosu MG. Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis. Ther Clin Risk Manag. 2015;11:759-66doi: 10.2147/TCRM.S69123.
Cocco, E., & Marrosu, M. G. (2015). Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis. Therapeutics and clinical risk management, 11759-66. https://doi.org/10.2147/TCRM.S69123
Cocco, Eleonora, and Marrosu, Maria Giovanna. "Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis." Therapeutics and clinical risk management vol. 11 (2015): 759-66. doi: https://doi.org/10.2147/TCRM.S69123
Cocco E, Marrosu MG. Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis. Ther Clin Risk Manag. 2015 May 08;11:759-66. doi: 10.2147/TCRM.S69123. eCollection 2015. PMID: 26056458; PMCID: PMC4431469.
Copy Download .nbib Format: NLM
Src is required for migration, phagocytosis, and interferon beta production in Toll-like receptor-engaged macrophages.

BioMedicine

Maa MC, Leu TH.
PMID: 27514533
Biomedicine (Taipei). 2016 Jun;6(3):14. doi: 10.7603/s40681-016-0014-4. Epub 2016 Aug 12.

As an evolutionarily conserved mechanism, innate immunity controls self-nonself discrimination to protect a host from invasive pathogens. Macrophages are major participants of the innate immune system. Through the activation of diverse Toll-like receptors (TLRs), macrophages are triggered to initiate...

Cite
Maa MC, Leu TH. Src is required for migration, phagocytosis, and interferon beta production in Toll-like receptor-engaged macrophages. Biomedicine (Taipei). 2016;6(3):14doi: 10.7603/s40681-016-0014-4.
Maa, M. C., & Leu, T. H. (2016). Src is required for migration, phagocytosis, and interferon beta production in Toll-like receptor-engaged macrophages. BioMedicine, 6(3), 14. https://doi.org/10.7603/s40681-016-0014-4
Maa, Ming-Chei, and Leu, Tzeng-Horng. "Src is required for migration, phagocytosis, and interferon beta production in Toll-like receptor-engaged macrophages." BioMedicine vol. 6,3 (2016): 14. doi: https://doi.org/10.7603/s40681-016-0014-4
Maa MC, Leu TH. Src is required for migration, phagocytosis, and interferon beta production in Toll-like receptor-engaged macrophages. Biomedicine (Taipei). 2016 Jun;6(3):14. doi: 10.7603/s40681-016-0014-4. Epub 2016 Aug 12. PMID: 27514533; PMCID: PMC4980824.
Copy Download .nbib Format: NLM
Correction: Polygonum cuspidatum and its active components inhibit replication of the influenza virus through toll-like receptor 9-induced interferon beta expression.

PloS one

Lin CJ, Lin HJ, Chen TH, Hsu YA, Liu CS, Hwang GY, Wan L.
PMID: 25860479
PLoS One. 2015 Apr 10;10(4):e0125288. doi: 10.1371/journal.pone.0125288. eCollection 2015.

No abstract available.

Cite
Lin CJ, Lin HJ, Chen TH, et al. Correction: Polygonum cuspidatum and its active components inhibit replication of the influenza virus through toll-like receptor 9-induced interferon beta expression. PLoS One. 2015;10(4):e0125288doi: 10.1371/journal.pone.0125288.
Lin, C. J., Lin, H. J., Chen, T. H., Hsu, Y. A., Liu, C. S., Hwang, G. Y., & Wan, L. (2015). Correction: Polygonum cuspidatum and its active components inhibit replication of the influenza virus through toll-like receptor 9-induced interferon beta expression. PloS one, 10(4), e0125288. https://doi.org/10.1371/journal.pone.0125288
Lin, Chao-Jen, et al. "Correction: Polygonum cuspidatum and its active components inhibit replication of the influenza virus through toll-like receptor 9-induced interferon beta expression." PloS one vol. 10,4 (2015): e0125288. doi: https://doi.org/10.1371/journal.pone.0125288
Lin CJ, Lin HJ, Chen TH, Hsu YA, Liu CS, Hwang GY, Wan L. Correction: Polygonum cuspidatum and its active components inhibit replication of the influenza virus through toll-like receptor 9-induced interferon beta expression. PLoS One. 2015 Apr 10;10(4):e0125288. doi: 10.1371/journal.pone.0125288. eCollection 2015. PMID: 25860479; PMCID: PMC4393289.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 507 entries